Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

NCT04056689 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04056689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04056689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
July 23, 2019
Completion date
December 2, 2020
Enrollment
36 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease